Journal of Neurogastroenterology and Motility
Condition   Expression Quick Search
When you enter More than two words, please use ‘and , or’ operation by means of putting ‘,(Comma Mark)’ between each word.
 
Korean J Physiol Pharmacol 2018 Jan; 22(1): 63-70
Young-Seop Park1,3, Zhen Jin2, Eun Ae Jeong2, Chin-ok Yi2, Jong Youl Lee2, In Sung Park3,*, and Gu Seob Roh2,*
Cilostazol attenuates kainic acid-induced hippocampal cell death
1Department of Neurosurgery, Institute of Health Sciences, Gyeongsang National University Changwon Hospital, Changwon 51472, 2Department of Anatomy and Convergence Medical Science, Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju 52727, 3Department of Neurosurgery, Institute of Health Sciences, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju 52727, Korea
Cilostazol is a selective inhibitor of type 3 phosphodiesterase (PDE3) and has been widely used as an antiplatelet agent. Cilostazol mediates this activity through effects on the cyclic adenosine monophosphate (cAMP) signaling cascade. Recently, it has attracted attention as a neuroprotective agent. However, little is known about cilostazol’s effect on excitotoxicity induced neuronal cell death. Therefore, this study evaluated the neuroprotective effect of cilostazol treatment against hippocampal neuronal damage in a mouse model of kainic acid (KA)-induced neuronal loss. Cilostazol pretreatment reduced KA-induced seizure scores and hippocampal neuron death. In addition, cilostazol pretreatment increased cAMP response element-binding protein (CREB) phosphorylation and decreased neuroinflammation. These observations suggest that cilostazol may have beneficial therapeutic effects on seizure activity and other neurological diseases associated with excitotoxicity.
Keyword : Cilostazol, Hippocampus, Kainic acid, Neuroinflammation, Neuronal death